OUTLOOK THERAPEUTICS, INC. (OTLK) Current Ratio
- Current ratio · latest quarter: Value 0.81×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 0.81× | Current assets / current liabilities. $23.17M ÷ $28.68M ≈ 0.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 23.17M USD | Assets, Current |
| Current obligations | 28.68M USD | Liabilities, Current |
| Cash and equivalents | 11.24M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 5.04M USD | Inventory, Net |
| Payables | 6.81M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.17M | $28.68M | $11.24M | (m) | $1.64M | $5.04M | $6.81M | (m) | 0.81× |
| 2026-03-31 | $20.90M | $38.88M | $7.75M | (m) | $2.72M | $3.34M | $13.64M | (m) | 0.54× |
| 2025-12-31 | $17.17M | $49.06M | $8.68M | (m) | $114.61K | $3.46M | $7.32M | (m) | 0.35× |
| 2025-09-30 | $17.39M | $45.81M | $8.08M | (m) | $1.49M | $3.34M | $10.19M | (m) | 0.38× |
| 2025-06-30 | $21.10M | $31.49M | $8.90M | (m) | $1.75M | $4.13M | $10.26M | (m) | 0.67× |
| 2025-03-31 | $17.81M | $24.82M | $7.56M | (m) | (m) | $3.60M | $7.77M | (m) | 0.72× |
| 2024-12-31 | $15.67M | $48.24M | $5.70M | (m) | (m) | $3.11M | $12.19M | (m) | 0.32× |
| 2024-09-30 | $27.42M | $42.55M | $14.93M | (m) | (m) | (m) | $7.97M | (m) | 0.64× |
| 2024-06-30 | $45.62M | $42.55M | $32.02M | (m) | (m) | (m) | $5.55M | (m) | 1.07× |
| 2024-03-31 | $57.79M | $54.08M | $47.23M | (m) | (m) | (m) | $4.36M | (m) | 1.07× |
| 2023-12-31 | $20.39M | $45.97M | $10.36M | (m) | (m) | (m) | $3.48M | (m) | 0.44× |
| 2023-09-30 | $30.98M | $46.73M | $23.39M | (m) | (m) | (m) | $6.57M | (m) | 0.66× |
| 2023-06-30 | $43.02M | $49.93M | $33.71M | (m) | (m) | (m) | $5.06M | (m) | 0.86× |
| 2023-03-31 | $53.05M | $43.53M | $43.63M | (m) | (m) | (m) | $3.62M | (m) | 1.22× |
| 2022-12-31 | $61.68M | $15.08M | $52.34M | (m) | (m) | (m) | $4.17M | (m) | 4.09× |
| 2022-09-30 | $27.52M | $19.73M | $17.40M | (m) | (m) | (m) | $3.49M | (m) | 1.39× |
| 2022-06-30 | $37.51M | $18.43M | $26.02M | (m) | (m) | (m) | $2.48M | (m) | 2.04× |
| 2022-03-31 | $66.55M | $31.41M | $58.42M | (m) | (m) | (m) | $4.16M | (m) | 2.12× |
| 2021-12-31 | $77.47M | $19.95M | $70.15M | (m) | (m) | (m) | $2.55M | (m) | 3.88× |
| 2021-09-30 | $21.51M | $6.75M | $14.48M | (m) | (m) | (m) | $2.20M | (m) | 3.19× |
| 2021-06-30 | $31.90M | $19.64M | $19.69M | (m) | (m) | (m) | $2.67M | (m) | 1.62× |
| 2021-03-31 | $43.79M | $23.90M | $37.17M | (m) | (m) | (m) | $6.33M | (m) | 1.83× |
| 2020-12-31 | $11.03M | $12.12M | $5.57M | (m) | (m) | (m) | $3.33M | (m) | 0.91× |
| 2020-09-30 | $17.94M | $15.89M | $12.54M | (m) | (m) | (m) | $2.39M | (m) | 1.13× |
| 2020-06-30 | $28.24M | $18.45M | $23.95M | (m) | (m) | (m) | $5.01M | $422.13M | 1.53× |
| 2020-03-31 | $9.49M | $23.71M | $4.65M | (m) | (m) | (m) | $3.31M | (m) | 0.40× |
| 2019-12-31 | $6.54M | $20.10M | $1.33M | (m) | (m) | (m) | $2.57M | (m) | 0.33× |
| 2019-09-30 | $13.50M | $20.29M | $8.02M | (m) | (m) | (m) | $2.28M | (m) | 0.67× |
| 2019-06-30 | $18.81M | $23.22M | $14.03M | (m) | (m) | (m) | $2.99M | $1.05M | 0.81× |
| 2019-03-31 | $2.13M | $26.99M | $155.47K | (m) | (m) | (m) | $5.11M | $1.05M | 0.08× |
| 2018-12-31 | $2.31M | $27.54M | $227.72K | (m) | (m) | (m) | $4.70M | $56.54K | 0.08× |
| 2018-09-30 | $3.30M | $32.04M | $1.72M | (m) | (m) | (m) | $3.61M | $66.48K | 0.10× |
| 2018-06-30 | $13.13M | $32.26M | $11.80M | (m) | (m) | (m) | $3.35M | $86.73K | 0.41× |
| 2018-03-31 | $6.92M | $31.75M | $5.94M | (m) | (m) | (m) | $3.61M | $102.91K | 0.22× |
| 2017-12-31 | $15.35M | $31.20M | $13.84M | (m) | (m) | (m) | $3.63M | $118.76K | 0.49× |
| 2017-09-30 | $3.90M | $28.74M | $3.19M | (m) | (m) | (m) | $10.95M | $52.60K | 0.14× |
| 2017-06-30 | $1.19M | $39.27M | $139.90K | (m) | (m) | (m) | $11.79M | (m) | 0.03× |
| 2017-03-31 | $854.68K | $34.78M | $81.05K | (m) | (m) | (m) | $12.15M | (m) | 0.02× |
| 2016-12-31 | $3.17M | $32.13M | $2.08M | (m) | (m) | (m) | $11.05M | (m) | 0.10× |
| 2016-09-30 | $5.68M | $20.44M | $2.35M | (m) | (m) | (m) | $5.07M | $586.45K | 0.28× |
| 2016-06-30 | $14.86M | $22.94M | $13.56M | (m) | $3.67K | (m) | $4.53M | (m) | 0.65× |
| 2016-03-31 | $4.10M | $35.98M | $2.84M | (m) | $504.86K | (m) | $14.42M | (m) | 0.11× |
| 2015-09-30 | $15.16M | $37.04M | $9.07M | (m) | $20.00K | (m) | $11.56M | (m) | 0.41× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |